STE Healthcare

STERIS plc

$231.35-0.86%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 22.6B USD
Enterprise value: 23.1B USD
Full-time employees: 17,937

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.91 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.91 vs peers 0.63)
About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $3.1B in FY Mar 2021 to $5.9B in FY Mar 2026.
STERIS's fiscal-year revenue rose in each of the five years to FY Mar 2026, from $3.1B to $5.9B.
Profit is backed by cash. Free cash flow is 115% of reported profit.
STERIS's free cash flow is 115% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

59/ 100

Oct 5 60 → Nov 4 59 (-1)

Valuation

Is the price right?

65/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ EBITDA yield
▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield3.6%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 1.41Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.8%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.70Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield4.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield31.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

56/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Helped by:

▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth25.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.54Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth9.0%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.37Sector median: 0.0584 · MAD: 0.0840

Revenue growth8.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.23Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

78/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROA
▲ Operating margin
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin18.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.97Sector median: 0.0706 · MAD: 0.1217

Return on assets7.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.09Sector median: 0.0166 · MAD: 0.0537

Return on invested capital10.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.57Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin44.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity11.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.91

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.86Sector median: 0.6250 · MAD: 0.3380

Current ratio1.91×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.49Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.26×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.20Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about STERIS

Is STERIS getting weaker?: Its latest SEC filing (Aug 7, 2026) showed no major changes. Its overall score is unchanged at 59/100 since Oct 28, 2026.
How is STERIS valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 65/100 against 1,393 healthcare peers. EBITDA yield 6.8% vs a peer median of 4.0% (stronger than 68% of peers).EBITDA yield 6.8% vs peers 4.0% (stronger than 68% of peers).
Is STERIS growing?: At about the same pace as its peers. Growth scores 56/100 against 1,393 healthcare peers. Earnings per share growth 25.8% vs a peer median of 9.8% (stronger than 73% of peers).Earnings per share growth 25.8% vs peers 9.8% (stronger than 73% of peers).
How profitable is STERIS?: More profitable than most of its peers. Profitability scores 78/100 against 1,393 healthcare peers. Return on assets 7.5% vs a peer median of 1.7% (stronger than 84% of peers).Return on assets 7.5% vs peers 1.7% (stronger than 84% of peers).
How risky is STERIS?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.91 vs a peer median of 0.63 (weaker than 68% of peers).Beta 0.91 vs peers 0.63 (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 7, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	5.9B USD	6.0B USD	+1.7%
Net income (12 months)	782.3M USD	805.0M USD	+2.9%
Operating margin	18.6%	18.9%	+0.3 pts
Free cash flow (12 months)	972.4M USD	925.6M USD	−4.8%
Debt	1.9B USD	1.9B USD	−2.0%
Cash	439.6M USD	482.3M USD	+9.7%
Shares outstanding	97.6M	97.5M	−0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	FY Mar 2026	Change
Gross margin	44.6%	43.7%	43.2%	44.0%	44.2%	▲ 0.2 pts
Operating margin	11.3%	17.4%	16.3%	15.9%	18.6%	▲ 2.7 pts
Net margin	5.8%	2.4%	7.4%	11.3%	13.2%	▲ 1.9 pts
Return on assets (ROA)	2.1%	1.0%	3.4%	6.1%	7.3%	▲ 1.2 pts
Return on equity (ROE)	3.7%	1.8%	6.0%	9.3%	10.9%	▲ 1.6 pts
Free cash flow margin	9.4%	8.7%	11.9%	14.3%	16.4%	▲ 2.1 pts
Current ratio	2.04×	2.33×	3.08×	1.96×	2.09×	▲ 6.8%
Quick ratio	1.41×	1.63×	2.36×	1.39×	1.54×	▲ 11%
Debt to equity	0.47×	0.51×	0.51×	0.31×	0.27×	▼ 13%
Interest coverage	5.34×	7.33×	5.79×	10.04×	18.15×	▲ 81%

STE price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.91 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.91 vs peers 0.63)

About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $3.1B in FY Mar 2021 to $5.9B in FY Mar 2026.

STERIS's fiscal-year revenue rose in each of the five years to FY Mar 2026, from $3.1B to $5.9B.

Profit is backed by cash. Free cash flow is 115% of reported profit.

STERIS's free cash flow is 115% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about STERIS

Is STERIS getting weaker?

Its latest SEC filing (Aug 7, 2026) showed no major changes. Its overall score is unchanged at 59/100 since Oct 28, 2026.

How is STERIS valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 65/100 against 1,393 healthcare peers. EBITDA yield 6.8% vs a peer median of 4.0% (stronger than 68% of peers).EBITDA yield 6.8% vs peers 4.0% (stronger than 68% of peers).

Is STERIS growing?

At about the same pace as its peers. Growth scores 56/100 against 1,393 healthcare peers. Earnings per share growth 25.8% vs a peer median of 9.8% (stronger than 73% of peers).Earnings per share growth 25.8% vs peers 9.8% (stronger than 73% of peers).

How profitable is STERIS?

More profitable than most of its peers. Profitability scores 78/100 against 1,393 healthcare peers. Return on assets 7.5% vs a peer median of 1.7% (stronger than 84% of peers).Return on assets 7.5% vs peers 1.7% (stronger than 84% of peers).

How risky is STERIS?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.91 vs a peer median of 0.63 (weaker than 68% of peers).Beta 0.91 vs peers 0.63 (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

5.9B USD

6.0B USD

+1.7%

Net income (12 months)

782.3M USD

805.0M USD

+2.9%

Operating margin

18.6%

18.9%

+0.3 pts

Free cash flow (12 months)

972.4M USD

925.6M USD

−4.8%

Debt

1.9B USD

1.9B USD

−2.0%

Cash

439.6M USD

482.3M USD

+9.7%

Shares outstanding

97.6M

97.5M

−0.1%

Key ratios

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

FY Mar 2026

Change

Gross margin

44.6%

43.7%

43.2%

44.0%

44.2%

▲ 0.2 pts

Operating margin

11.3%

17.4%

16.3%

15.9%

18.6%

▲ 2.7 pts

Net margin

5.8%

2.4%

7.4%

11.3%

13.2%

▲ 1.9 pts

Return on assets (ROA)

2.1%

1.0%

3.4%

6.1%

7.3%

▲ 1.2 pts

Return on equity (ROE)

3.7%

1.8%

6.0%

9.3%

10.9%

▲ 1.6 pts

Free cash flow margin

9.4%

8.7%

11.9%

14.3%

16.4%

▲ 2.1 pts

Current ratio

2.04×

2.33×

3.08×

1.96×

2.09×

▲ 6.8%

Quick ratio

1.41×

1.63×

2.36×

1.39×

1.54×

▲ 11%

Debt to equity

0.47×

0.51×

0.31×

0.27×

▼ 13%

Interest coverage

5.34×

7.33×

5.79×

10.04×

18.15×

▲ 81%